Blocklisting Six Monthly Return

RNS Number : 2826K
Hutchison China Meditech Limited
29 December 2015
 



 

 

 

Blocklisting Six Monthly Return

 

 

London: Tuesday, 29 December 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) announces the following blocklisting six monthly return:

 

1.

Name of applicant:

 


Hutchison China MediTech Limited

2.

Name of scheme:

 


Hutchison China MediTech Limited Share Option Scheme

 

3.

Period of return:                                 

 


From 29 June 2015 to 28 December 2015

4.

Balance under scheme from previous return:

 


472,763 ordinary shares of US$1 each

 

5.

The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:

 


Nil

6.

Number of securities issued/allotted under scheme during period:


18,750 ordinary shares of US$1 each





7.

Balance under scheme not yet issued/allotted at end of the period:

 


454,013 ordinary shares of US$1 each

8.

Number and class of securities originally listed and the date of admission:

 


2,560,606 ordinary shares of US$1 each admitted on 26 June 2007

9.

Total number of securities in issue at the end of the period:


56,533,118 ordinary shares of US$1 each





Name of contact:

 


Christian Hogg

Address of contact:

 


21/F., Hutchison House, 10 Harcourt Road, Hong Kong

 

Telephone number of contact:

 


+852 2121 8200

 

 

Ends

 

 

Enquiries

 

Chi-Med

Christian Hogg, CEO

Telephone:      +852 2121 8200

 



Panmure Gordon (UK) Limited

Telephone:      +44 20 7886 2500

Richard Gray

Andrew Potts

 

 



Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone:      +44 20 7638 9571

Mobile:             +44 7973 611 888

Mobile:             +44 7967 566 919

 

 

Notes to Editors

About Chi-Med

 

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products.  Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001).  For more information, please visit: www.chi-med.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRUKABRVAAUURA
UK 100